Skip to content
AnalystLens

BridgeBio Pharma 8-K Report, Executive Changes (Mar 17, 2025)

Reports
Leadership Changes·Regulation FD·Exhibits & Filings
Filing Date
Filed March 17, 2025
Period End
March 17, 2025
Security
BBIO
In the record · 2019–202610-K710-Q238-K107

BBIO filed 7 annual reports (10-K), 23 quarterly reports (10-Q) and 107 current reports (8-K) between 2019 and 2026.

  1. Leadership change8-K · Feb ’20Feb ’20
  2. Leadership change8-K · Oct ’21Oct ’21
  3. Material agreement8-K · Sep ’23Sep ’23
  4. Material agreement8-K · Aug ’26Aug ’26

Summary

Summary of the 8-K filed March 17, 2025. Cited figures are marked; the original filing is the authoritative source.

On March 17, 2025, BridgeBio Pharma, Inc. (Nasdaq: BBIO) reported under Item 5.02 that Brian C.

Stephenson, its Chief Financial Officer, ended employment with the Company on that date. In connection with his transition, Dr. Stephenson will receive a lump sum payment equal to nine months of his current base salary and up to nine months of COBRA reimbursements, under his employment offer letter as amended on February 21, 2024. The Company also entered into a consulting agreement with Dr. Stephenson, under which he will provide consulting services from March 17, 2025 through March 17, 2026, unless earlier terminated.

The full consulting agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ending March 31, 2025. Under Item 7.01, the Company announced that Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer. Dr. Trimarchi recently assumed the role of Principal Financial Officer and will continue to lead the Company's FP&A and accounting operations.

According to the press release furnished as Exhibit 99.1, Dr. Stephenson is departing for personal reasons, not due to any disagreement with the Company on operations, policies or practices, and will continue to serve as a consultant. For investors, the filing signals a leadership change in the finance function, with continuity provided by the consulting arrangement and by Dr. Trimarchi's existing responsibility for FP&A and accounting. The filing does not describe any financial results or operational developments beyond these personnel changes.

Key Highlights

  1. Brian C. Stephenson's employment as CFO ended March 17, 2025.
  2. Thomas Trimarchi, Ph.D. was appointed President and Chief Financial Officer, having recently assumed the Principal Financial Officer role.
  3. Dr. Stephenson will receive a lump sum equal to nine months of current base salary plus up to nine months of COBRA reimbursements.
  4. Dr. Stephenson will serve as a consultant from March 17, 2025 through March 17, 2026, unless earlier terminated.
  5. The company states the departure was for personal reasons and not the result of a disagreement on operations, policies or practices.
  6. Dr. Trimarchi will continue to lead FP&A and accounting operations.
  7. The full consulting agreement will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2025.

Frequently Asked Questions

  1. Why did the CFO leave BridgeBio?

    The press release states that Dr. Stephenson is departing for personal reasons. The company says the departure was not the result of any disagreement on its operations, policies or practices.

  2. Who is the new CFO?

    Thomas Trimarchi, Ph.D. has been appointed President and Chief Financial Officer. He recently assumed the role of Principal Financial Officer and will continue to lead FP&A and accounting operations.

  3. What severance terms apply to the former CFO?

    Under his employment offer letter, as amended February 21, 2024, Dr. Stephenson will receive a lump sum equal to nine months of his current base salary and up to nine months of COBRA reimbursements.

  4. Will the former CFO remain involved with the company?

    Yes. Dr. Stephenson will provide consulting services to the Company from March 17, 2025 through March 17, 2026, unless the consulting agreement is terminated earlier.

  5. Where can investors find the full terms of the consulting agreement?

    The filing states that the consulting agreement will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2025.